13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001582844
Total reported value
$143.5M
$143.5M
33 檔
43.2%
During the Q1 2024 filing period, Acuta Capital Partners, LLC (CIK: 0001582844) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $143.5M across 33 reported positions.
During Q1 2024, Acuta Capital Partners, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | OCUL | Ocular Therapeutix Inc | Stock-Other | 15.58% | +0.07% | +101.17% | |
| 2 | PRAX | Praxis Precision Medicines I | Stock-Other | 6.43% | -0.13% | -45.83% | |
| 3 | ✓ | Mersana Therapeutics Inc | Stock-Other | 6.30% | — | -8.59% | |
| 4 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 6.21% | +1.27% | -7.13% | |
| 5 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 5.72% | — | -10.72% | |
| 6 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 5.40% | — | -9.12% | |
| 7 | PCVX | Vaxcyte Inc | Stock-Other | 4.65% | — | -10.69% | |
| 8 | ELVN | Enliven Therapeutics Inc | Stock-Other | 4.53% | — | +219.75% | |
| 9 | TRML | Tourmaline Bio Inc | Stock-Other | 3.88% | — | +12.60% | |
| 10 | APLT | Applied Therapeutics Inc | Stock-Other | 3.50% | — | +50.83% | |
| 11 | DYN | Dyne Therapeutics Inc | Stock-Other | 3.40% | — | +24.80% | |
| 12 | IRON | Disc Medicine Inc | Stock-Other | 3.11% | — | -33.51% | |
| 13 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.01% | -1.80% | EXIT | |
| 14 | CLDX | Celldex Therapeutics Inc | Stock-Other | 2.97% | — | +57.06% | |
| 15 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 2.81% | +6.59% | — | |
| 16 | ✓ | Hillevax Inc | Stock-Other | 2.71% | — | -22.79% | |
| 17 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.38% | — | -10.40% | |
| 18 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.27% | — | -29.15% | |
| 19 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.98% | -18.59% | EXIT | |
| 20 | IMVT | Immunovant Inc | Stock-Other | 1.94% | — | -22.72% | |
| 21 | VSTM | Verastem Inc | Stock-Other | 1.59% | — | -10.83% | |
| 22 | ACLXGBX | Arcellx Inc | Stock-Other | 1.56% | — | -55.19% | |
| 23 | KURA | Kura Oncology Inc | Stock-Other | 1.25% | — | -87.17% | |
| 24 | INSM | Insmed Inc | Stock-Healthcare | 1.09% | — | +109.21% | |
| 25 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.05% | — | — | |
| 26 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.93% | — | — | |
| 27 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.85% | — | — | |
| 28 | LYRAGBP | Lyra Therapeutics Inc | Stock-Other | 0.70% | — | — | |
| 29 | CYPH | Cypherpunk Technologies Inc | Stock-Other | 0.61% | — | — | |
| 30 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.61% | — | — | |
| 31 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 0.60% | — | — | |
| 32 | CLRBUSD | Cellectar Biosciences Inc | Stock-Other | 0.37% | — | -69.95% | |
| 33 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.02% | — | — |
According to official SEC Form 13F filings, Acuta Capital Partners, LLC reported a total U.S. public equity portfolio value of $143.5M across 33 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including OCUL, PRAX, MERSANA THERAPEUTICS INC) accounted for 43.2% of total reported equity market value during Q1 2024.
During Q1 2024, Acuta Capital Partners, LLC's top holdings by market value included OCUL (15.6%)、PRAX (6.4%)、MERSANA THERAPEUTICS INC (6.3%). The largest single position, OCUL, represented 15.6% of total portfolio value.
In Q1 2024, Acuta Capital Partners, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.